In a recent filing with the Securities and Exchange Commission, Duey Marc, a director at Aprea Therapeutics, Inc. (NASDAQ:APRE), reported the purchase of common stock in the company. The transaction, which took place on October 14, involved the acquisition of 190 shares at a price of $2.58 per share, amounting to a total of $490. Following this purchase, Marc holds 210,113 shares directly. Additionally, Marc's spouse holds 602 shares indirectly, though Marc disclaims beneficial ownership of these securities.
InvestingPro Insights
The recent insider purchase by Director Duey Marc aligns with some interesting financial metrics and trends for Aprea Therapeutics, Inc. (NASDAQ:APRE). According to InvestingPro data, the company's market capitalization stands at a modest $16.57 million, reflecting its current position in the biotech sector.
One of the key InvestingPro Tips highlights that Aprea holds more cash than debt on its balance sheet, which could be seen as a positive sign for a small-cap biotech company. This financial cushion may provide some reassurance to investors like Marc who are increasing their stakes in the company.
However, it's worth noting that Aprea is quickly burning through cash, another InvestingPro Tip that investors should consider. This rapid cash burn is not uncommon for biotech firms in development stages but underscores the importance of successful clinical trials and potential partnerships for the company's future.
Interestingly, Aprea has seen a significant return over the last week, with a 19.14% price increase. This recent uptick could have influenced Marc's decision to purchase additional shares, possibly viewing it as an opportune moment to strengthen his position in the company.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Aprea Therapeutics, providing a deeper insight into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.